Michael Moore

Dr. Moore was the Founder and Chairman of Mission Therapeutics and PsiOxus Therapeutics with each of which he continues to serve as a non-executive director.

He also holds non-executive positions with Chronos Therapeutics and NASDAQ-listed Trillium Therapeutics Inc. Dr. Moore was previously CEO of Piramed Limited, a UK-based biotechnology company that was acquired by Roche in 2008. Prior to Piramed, Dr. Moore held progressive positions at Xenova Group plc (1988-2003), including Research Director and CSO.

Dr. Moore’s academic career included a tenured appointment at the Paterson Institute for Cancer Research (1980) and the University of Manchester Medical School where he was an Honorary Reader in immunology and oncology (1986). Dr. Moore is also a past Chairman of Cancer Research UK’s drug discovery committee.